Stocks

Magazine articles on individual stocks, valuation, accounting standards, IPO's, brokerages, exchanges.

Old Articles: <Older 51531-51540 Newer>

The Motley Fool August 29, 2011 Brian Orelli	We Can Make More! Too Bad Few Want It Dendreon is no longer constrained by its supply.
The Motley Fool August 29, 2011 Rich Smith	Fortress Investment Group Shares Surged: What You Need to Know Shares of private equity player Fortress Investment Group leapt 10% in Monday trading. Even if you think their business is just a little bit slimy, the sight of folks making a quick 10% profit probably got your attention.
The Motley Fool August 29, 2011 Tim Beyers	Listen Up! Research In Motion Wants Your Ears BBM Music seeks to challenge on-the-go music services.
The Motley Fool August 29, 2011 Zeeshan Siddique	Shell's Arrow Targets Bow Energy Firming up its footing in the liquefied natural gas business.
The Motley Fool August 29, 2011 Isac Simon	How Valuable Is Canadian Natural Resources? The company's assets must be capable of generating profitable returns.
The Motley Fool August 29, 2011 Brian Orelli	Drug Approved for Few Patients -- but That's OK The age of personalized medicine is upon us. Earlier this month, the FDA approved Roche's melanoma drug Zelboraf for patients with a specific mutation in BRAF. And on Friday, the agency approved Pfizer's Xalkori for lung cancer patients that are ALK-positive.
The Motley Fool August 29, 2011 Seth Jayson	Here's How Omnicell Is Making You So Much, So Fast With both 12-month and quarterly CCC running better than average, Omnicell gets high marks in this cash-conversion checkup.
The Motley Fool August 29, 2011 Selena Maranjian	Here's What Bruce Berkowitz Is Buying at Fairholme With a return of 132% vs. 0% for the S&P 500, his results demand our attention.
The Motley Fool August 29, 2011 Shubh Datta	Ralcorp Brings In the Dough Ralcorp looks to buy Sara Lee's refrigerated dough business for $545 million.
The Motley Fool August 29, 2011 Anders Bylund	Idenix Pharmaceuticals' Shares Popped: What You Need to Know Shares of viral-disease medication developer Idenix Pharmaceuticals climbed 10.9% on vanishingly thin trading volume.
<Older 51531-51540 Newer> Return to current articles.